PHARMANUTRA S.P.A.
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It also offers iron deficien… Read more
Market Cap & Net Worth: PHARMANUTRA S.P.A. (761)
PHARMANUTRA S.P.A. (F:761) has a market capitalization of $656.64 Million (€639.71 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #12980 globally and #1373 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PHARMANUTRA S.P.A.'s stock price €66.70 by its total outstanding shares 9590822 (9.59 Million).
PHARMANUTRA S.P.A. Market Cap History: 2021 to 2026
PHARMANUTRA S.P.A.'s market capitalization history from 2021 to 2026. Data shows growth from $703.28 Million to $656.64 Million (13.34% CAGR).
PHARMANUTRA S.P.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PHARMANUTRA S.P.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 761 by Market Capitalization
Companies near PHARMANUTRA S.P.A. in the global market cap rankings as of March 18, 2026.
Key companies related to PHARMANUTRA S.P.A. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
PHARMANUTRA S.P.A. Historical Marketcap From 2021 to 2026
Between 2021 and today, PHARMANUTRA S.P.A.'s market cap moved from $703.28 Million to $ 656.64 Million, with a yearly change of 13.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €656.64 Million | +24.67% |
| 2025 | €526.69 Million | -0.74% |
| 2024 | €530.63 Million | -2.31% |
| 2023 | €543.19 Million | -9.27% |
| 2022 | €598.67 Million | -14.87% |
| 2021 | €703.28 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of PHARMANUTRA S.P.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $656.64 Million USD |
| MoneyControl | $656.64 Million USD |
| MarketWatch | $656.64 Million USD |
| marketcap.company | $656.64 Million USD |
| Reuters | $656.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.